Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

T cell-derived IL-17 mediates epithelial changes in the airway and drives pulmonary neutrophilia.

Laura K Fogli | Mark S Sundrud | Swati Goel | Sofia Bajwa | Kari Jensen | Emmanuel Derudder | Amy Sun | Maryaline Coffre | Catherine Uyttenhove | Jacques Van Snick | Marc Schmidt-Supprian | Anjana Rao | Gabriele Grunig | Joan Durbin | Stefano Casola | Klaus Rajewsky | Sergei B Koralov
Journal of immunology (Baltimore, Md. : 1950) | 2013

Th17 cells are a proinflammatory subset of effector T cells that have been implicated in the pathogenesis of asthma. Their production of the cytokine IL-17 is known to induce local recruitment of neutrophils, but the direct impact of IL-17 on the lung epithelium is poorly understood. In this study, we describe a novel mouse model of spontaneous IL-17-driven lung inflammation that exhibits many similarities to asthma in humans. We have found that STAT3 hyperactivity in T lymphocytes causes an expansion of Th17 cells, which home preferentially to the lungs. IL-17 secretion then leads to neutrophil infiltration and lung epithelial changes, in turn leading to a chronic inflammatory state with increased mucus production and decreased lung function. We used this model to investigate the effects of IL-17 activity on airway epithelium and identified CXCL5 and MIP-2 as important factors in neutrophil recruitment. The neutralization of IL-17 greatly reduces pulmonary neutrophilia, underscoring a key role for IL-17 in promoting chronic airway inflammation. These findings emphasize the role of IL-17 in mediating neutrophil-driven pulmonary inflammation and highlight a new mouse model that may be used for the development of novel therapies targeting Th17 cells in asthma and other chronic pulmonary diseases.

Pubmed ID: 23966625

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NIAID NIH HHS, United States
    Id: R01 AI040127
  • Agency: NIAID NIH HHS, United States
    Id: AI40127
  • Agency: NCI NIH HHS, United States
    Id: 2P30CA016087-33
  • Agency: NCI NIH HHS, United States
    Id: CA42471
  • Agency: NCI NIH HHS, United States
    Id: R01 CA042471
  • Agency: NHLBI NIH HHS, United States
    Id: 1R01 HL095764-01
  • Agency: NCI NIH HHS, United States
    Id: R37 CA042471
  • Agency: NCI NIH HHS, United States
    Id: F31 CA171596
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL095764

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

We have not found any resources mentioned in this publication.